公开(公告)号：US20180243298A1

公开(公告)日：2018-08-30

申请号：US15563888

申请日：2016-03-30

Applicant: AbbVie Inc.

Inventor： Lawrence Black ,  Brian S. Brown ,  Bruce Clapham ,  Marlon D. Cowart ,  Michael J. Dart ,  Ramin Faghih ,  Jennifer Frost ,  Arthur R. Gomtsyan ,  Philip R. Kym ,  Huaqing Liu ,  Robert G. Schmidt ,  Lei Shi ,  Anurupa Shrestha ,  Kevin Sippy

IPC: A61K31/506 ,  A61P17/06 ,  A61P17/04

CPC classification number: A61K31/506 ,  A61P17/04 ,  A61P17/06 ,  C07D417/12 ,  C07D417/14 ,  C07D491/048 ,  C07D491/107

Abstract: A compound of Formula (I) having efficacy for the treatment or prevention of conditions and disorders related to TRPV3 activity, e.g. pain, atopic dermatitis, eczema, itch or psoriasis, is disclosed. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

公开(公告)号：US08859584B2

公开(公告)日：2014-10-14

申请号：US13716837

申请日：2012-12-17

Applicant: AbbVie Inc.

Inventor： Kevin R. Woller ,  Gregory A. Gfesser ,  Huaqing Liu ,  Jerome F. Daanen ,  Eric A. Voight ,  Irene I. Drizin ,  Anurupa Shrestha ,  Kathleen H. Mortell ,  Philip R. Kym ,  Michael E. Kort ,  Arthur Gomtsyan

IPC: A61K31/44 ,  A61K31/35 ,  A61K31/47 ,  A61K31/17 ,  C07D215/46 ,  C07D498/02 ,  C07D311/68 ,  A61K45/06 ,  C07D311/96 ,  C07D311/04 ,  C07C275/30 ,  A61K31/192 ,  C07D311/70 ,  A61K31/353 ,  C07D491/052 ,  A61K31/436 ,  C07D215/42 ,  C07C275/32

CPC classification number: C07D311/04 ,  A61K31/17 ,  A61K31/192 ,  A61K31/353 ,  A61K31/436 ,  A61K31/47 ,  A61K45/06 ,  C07C275/30 ,  C07C275/32 ,  C07D215/42 ,  C07D215/46 ,  C07D311/68 ,  C07D311/70 ,  C07D311/96 ,  C07D491/052

Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，其中X1，L，Rx，Ry，Rz，A，m，n，p，q，s和位置a和b如本说明书中所定义 。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。

公开(公告)号：US09777020B2

公开(公告)日：2017-10-03

申请号：US14603043

申请日：2015-01-22

Applicant: AbbVie Inc.

Inventor： Robert J. Altenbach ,  Huaqing Liu ,  Bruce Clapham ,  Ana L. Aguirre ,  Marlon Cowart ,  John R. Koenig ,  Kathy Sarris ,  Marc J. Scanio ,  Kerren K. Swinger ,  Anil Vasudevan ,  Clara I. Villamil ,  Kevin R. Woller

IPC: C07D407/12 ,  C07D491/048 ,  C07D491/20 ,  C07D519/00 ,  C07D307/83 ,  C07D405/12 ,  C07D491/107 ,  C07D493/10

CPC classification number: C07D519/00 ,  C07D307/83 ,  C07D405/12 ,  C07D407/12 ,  C07D491/048 ,  C07D491/107 ,  C07D491/20 ,  C07D493/10

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US20130158067A1

公开(公告)日：2013-06-20

申请号：US13716837

申请日：2012-12-17

Applicant: AbbVie Inc.

Inventor： Kevin R. Woller ,  Gregory A. Gfesser ,  Huaqing Liu ,  Jerome F. Daanen ,  Eric A. Voight ,  Irene I. Drizin ,  Anurupa Shrestha ,  Kathleen H. Mortell ,  Philip R. Kym ,  Michael E. Kort ,  Arthur Gomtsyan

IPC: C07D311/04 ,  A61K45/06 ,  A61K31/192 ,  C07D311/96 ,  A61K31/436 ,  A61K31/47 ,  C07C275/30 ,  A61K31/17 ,  C07C275/32 ,  C07D491/052 ,  A61K31/353 ,  C07D215/46

CPC classification number: C07D311/04 ,  A61K31/17 ,  A61K31/192 ,  A61K31/353 ,  A61K31/436 ,  A61K31/47 ,  A61K45/06 ,  C07C275/30 ,  C07C275/32 ,  C07D215/42 ,  C07D215/46 ,  C07D311/68 ,  C07D311/70 ,  C07D311/96 ,  C07D491/052

Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，其中X1，L，Rx，Ry，Rz，A，m，n，p，q，s和位置a和b如本说明书中所定义 。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。

公开(公告)号：US20200255423A1

公开(公告)日：2020-08-13

申请号：US16654219

申请日：2019-10-16

Applicant: AbbVie Inc.

Inventor： Maria A. Argiriadi ,  Eric C. Breinlinger ,  Ellen Yulin Tsai Chien ,  Marlon D. Cowart ,  Kristine E. Frank ,  Michael M. Friedman ,  David J. Hardee ,  J. Martin Herold ,  Huaqing Liu ,  Wei Qiu ,  Marc J. Scanio ,  Michael R. Schrimpf ,  Thomas R. Vargo ,  Stacy A. Van Epps ,  Matthew P. Webster ,  Andrew J. Little ,  Matthew H. Katcher ,  Theresa A. Dunstan ,  David A. Schiedler

IPC: C07D471/04 ,  C07D487/04

Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.

公开(公告)号：US20190276450A1

公开(公告)日：2019-09-12

申请号：US16299485

申请日：2019-03-12

Applicant: AbbVie Inc.

Inventor： Maria A. Argiriadi ,  Eric C. Breinlinger ,  Ellen Yulin Tsai Chien ,  Marlon D. Cowart ,  Kristine E. Frank ,  Michael M. Friedman ,  David J. Hardee ,  J. Martin Herold ,  Huaqing Liu ,  Wei Qiu ,  Marc J. Scanio ,  Michael R. Schrimpf ,  Thomas R. Vargo ,  Stacy A. Van Epps ,  Matthew P. Webster ,  Andrew J. Little ,  Matthew H. Katcher

IPC: C07D471/04

Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.

公开(公告)号：US10508113B2

公开(公告)日：2019-12-17

申请号：US16299485

申请日：2019-03-12

Applicant: AbbVie Inc.

Inventor： Maria A. Argiriadi ,  Eric C. Breinlinger ,  Ellen Yulin Tsai Chien ,  Marlon D. Cowart ,  Kristine E. Frank ,  Michael M. Friedman ,  David J. Hardee ,  J. Martin Herold ,  Huaqing Liu ,  Wei Qiu ,  Marc J. Scanio ,  Michael R. Schrimpf ,  Thomas R. Vargo ,  Stacy A. Van Epps ,  Matthew P. Webster ,  Andrew J. Little ,  Matthew H. Katcher

IPC: C07D405/14 ,  C07D471/04

Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, nad n are as defined herein, pharmaeceutical compositions 2C X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.

公开(公告)号：US20160130282A1

公开(公告)日：2016-05-12

申请号：US14934510

申请日：2015-11-06

Applicant: AbbVie Inc.

Inventor： Marlon D. Cowart ,  Huaqing Liu ,  Robert Altenbach

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.

公开(公告)号：US20150210720A1

公开(公告)日：2015-07-30

申请号：US14603043

申请日：2015-01-22

Applicant: AbbVie Inc.

Inventor： Robert J. Altenbach ,  Huaqing Liu ,  Bruce Clapham ,  Ana L. Aguirre ,  Marlon Cowart ,  John R. Koenig ,  Katerina Sarris ,  Marc J. Scanio ,  Kerren K. Swinger ,  Anil Vasudevan ,  Clara I. Villamil ,  Kevin R. Woller

IPC: C07D519/00 ,  C07D493/10 ,  C07D405/12 ,  C07D491/20 ,  C07D307/83 ,  C07D491/048 ,  C07D491/107

CPC classification number: C07D519/00 ,  C07D307/83 ,  C07D405/12 ,  C07D407/12 ,  C07D491/048 ,  C07D491/107 ,  C07D491/20 ,  C07D493/10

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract translation: 式（I）化合物及其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，Z1，Z2和n如说明书中所定义，可用于治疗由Tropomysin受体阻止或改善的病症或病症 激酶（Trk）。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。